Download PDF
Horm Metab Res 2013; 45(07): 485-489
DOI: 10.1055/s-0033-1333765
Original Basic
© Georg Thieme Verlag KG Stuttgart · New York

Characterization of the Specificity of Imidazoline I-1 Receptor Antibody for Subtype of Imidazoline Receptors In Vitro

L.-Y. Wang
1   Department of Pediatrics, Department of Medical Research, Chi-Mei Medical Center, Yong Kang, Tainan City, Taiwan
2   The Center of General Education, Chia Nan University of Pharmacy & ­Science, Rende Dist, Tainan City, Taiwan
,
P.-M. Ku
3   Department of Cardiology, Department of Medical Research, Chi-Mei Medical Center, Yong Kang, Tainan City, Taiwan
,
S.-H. Chen
4   Department of Obstetrics and Gynecology, Department of Medical Research, Chi-Mei Medical Center, Yong Kang, Tainan City, Taiwan
5   Department of Medical Research, Chi-Mei Medical Center, Yong Kang, Tainan City, Taiwan
,
L.-J. Chen
6   Institute of Basic Medical Sciences, College of Medicine, National Cheng Kung University, Tainan City, Taiwan
,
Y.-M. Yu
7   Department of Nutrition and Institute of Medical Science, College of Health Science, Chang Jung Christian University, Guei-Ren, Tainan City, Taiwan
,
J.-T. Cheng
5   Department of Medical Research, Chi-Mei Medical Center, Yong Kang, Tainan City, Taiwan
6   Institute of Basic Medical Sciences, College of Medicine, National Cheng Kung University, Tainan City, Taiwan
› Author Affiliations
Further Information

Publication History

received 04 November 2012

accepted 18 January 2013

Publication Date:
21 February 2013 (online)

Also available at
    Permissions and Reprints

Abstract

Specific antibodies are essential in the study of receptor protein. Gene matching shows that Nischarin (NISCH) is a mouse homologue of human imidazoline receptor antisera-selective (IRAS) protein, a viable candidate for imidazoline I-1 receptor. However, selectivity of this antibody against imidazoline I-2 or imidazoline I-3 receptors remained obscure. At first, an intracerebroventricular (ICV) injection of anti-NISCH antibody blocked the blood pressure lowering action of rilmenidine (I-1 receptor agonist) in spontaneous hypertensive rat (SHR). However, the same injection of anti-NISCH antibody showed no effect in SHR treated with clonidine (α2 agonist). In order to clarify the selectivity of anti-NISCH antibody for each subtype of imidazoline receptors, this anti-NISCH antibody was subjected to the lysate of organs isolated from Wistar rats including cortex, hippocampus, cerebellum, and brain stem as central nervous tissues, and heart, liver, pancreas, skeletal muscle, kidney, prostate, and bladder as peripheral tissues. The results show that anti-NISCH antibody positively reacted with all tissues including heart, pancreas, skeletal muscle, kidney and bladder by Western blot analysis. Also, the blotting spots for anti-NISCH antibody show a concentration-dependent manner. Moreover, anti-NISCH antibody blocked the action of glucose uptake induced by 2-BFI (I-2 receptor agonist) in L6 cells. Taken together, the obtained data suggest that anti-NISCH antibody can be used not only for imidazoline I-1 receptor but also for I-2 and I-3 subtypes in immunoassays.

Key words

imidazoline I-1 receptor - imidazoline I-2 receptor - imidazoline I-3 receptor - Nischarin (HISCH) - imidazoline receptor antisera-selective (IRAS) protein
 

  • References

  • 1 Bousquet P, Feldman J, Schwartz J. Central cardiovascular effects of alpha adrenergic drugs: differences between catecholamines and imidazolines. J Pharmacol Exp Ther 1984; 230: 232-236
    PubMedGoogle Scholar
  • 2 Michel MC, Insel PA. Are there multiple imidazoline binding sites?. Trends Pharmacol Sci 1989; 10: 342-344
    CrossrefPubMedGoogle Scholar
  • 3 Chan SL, Brown CA, Scarpello KE, Morgan NG. The imidazoline site involved in control of insulin secretion: characteristics that distinguish it from I1- and I2-sites. Br J Pharmacol 1994; 112: 1065-1070
    CrossrefPubMedGoogle Scholar
  • 4 Morgan NG, Chan SL, Mourtada M, Monks LK, Ramsden CA. Imidazolines and pancreatic hormone secretion. Ann N Y Acad Sci 1999; 881: 217-228
    CrossrefPubMedGoogle Scholar
  • 5 Mayer G, Taberner PV. Effects of the imidazoline ligands efaroxan and KU14R on blood glucose homeostasis in the mouse. Eur J Pharmacol 2002; 454: 95-102
    CrossrefPubMedGoogle Scholar
  • 6 Escriba PV, Ozaita A, Garcia-Sevilla JA. Pharmacologic characterization of imidazoline receptor proteins identified by immunologic techniques and other methods. Ann N Y Acad Sci 1999; 881: 8-25
    CrossrefPubMedGoogle Scholar
  • 7 Dontenwill M, Vonthron C, Greney H, Magnier C, Heemskerk F, Bousquet P. Identification of human I1 receptors and their relationship to alpha 2-adrenoceptors. Ann N Y Acad Sci 1999; 881: 123-134
    CrossrefPubMedGoogle Scholar
  • 8 Heemskerk FM, Dontenwill M, Greney H, Vonthron C, Bousquet P. Evidence for the existence of imidazoline-specific binding sites in synaptosomal plasma membranes of the bovine brainstem. J Neurochem 1998; 71: 2193-2202
    PubMedGoogle Scholar
  • 9 Tesson F, Parini A. Identification of an imidazoline-guanidinium receptive site in mitochondria from rabbit cerebral cortex. Eur J Pharmacol 1991; 208: 81-83
    CrossrefPubMedGoogle Scholar
  • 10 Tesson F, Limon I, Parini A. Tissue-specific localization of mitochondrial imidazoline-guanidinium receptive sites. Eur J Pharmacol 1992; 219: 335-338
    CrossrefPubMedGoogle Scholar
  • 11 Martin-Gomez JI, Ruiz J, Callado LF, Garibi JM, Aguinaco L, Barturen F, Javier Meana J. Increased density of I2-imidazoline receptors in human glioblastomas. Neuroreport 1996; 7: 1393-1396
    CrossrefPubMedGoogle Scholar
  • 12 Tesson F, Limon-Boulez I, Urban P, Puype M, Vandekerckhove J, Coupry I, Pompon D, Parini A. Localization of I2-imidazoline binding sites on monoamine oxidases. J Biol Chem 1995; 270: 9856-9861
    CrossrefPubMedGoogle Scholar
  • 13 Ulibarri I, Soto J, Ruiz J, Ballesteros J, Jauregui JV, Meana JJ. I2-imidazoline receptors in platelets of patients with Parkinson’s disease and Alzheimer’s type dementia. Ann N Y Acad Sci 1999; 881: 199-202
    CrossrefPubMedGoogle Scholar
  • 14 Raasch W, Muhle H, Dominiak P. Modulation of MAO activity by imidazoline and guanidine derivatives. Ann N Y Acad Sci 1999; 881: 313-331
    CrossrefPubMedGoogle Scholar
  • 15 Prince JT, Milona N, Stallcup WB. Characterization of a partial cDNA clone for the NILE glycoprotein and identification of the encoded polypeptide domain. J Neurosci 1989; 9: 1825-1834
    PubMedGoogle Scholar
  • 16 Piletz JE, Ivanov TR, Sharp JD, Ernsberger P, Chang CH, Pickard RT, Gold G, Roth B, Zhu H, Jones JC, Baldwin J, Reis DJ. Imidazoline receptor antisera-selected (IRAS) cDNA: cloning and characterization. DNA Cell Biol 2000; 19: 319-329
    CrossrefPubMedGoogle Scholar
  • 17 Alahari SK, Lee JW, Juliano RL. Nischarin, a novel protein that interacts with the integrin alpha5 subunit and inhibits cell migration. J Cell Biol 2000; 151: 1141-1154
    CrossrefPubMedGoogle Scholar
  • 18 Zhang J, Abdel-Rahman AA. Nischarin as a functional imidazoline (I1) receptor. FEBS Lett 2006; 580: 3070-3074
    CrossrefPubMedGoogle Scholar
  • 19 Obregon D, Hou H, Deng J, Giunta B, Tian J, Darlington D, Shahaduzzaman M, Zhu Y, Mori T, Mattson MP, Tan J. Soluble amyloid precursor protein-alpha modulates beta-secretase activity and amyloid-beta generation. Nature Commun 2012; 3: 777
    CrossrefPubMedGoogle Scholar
  • 20 Zhu QM, Lesnick JD, Jasper JR, MacLennan SJ, Dillon MP, Eglen RM, Blue Jr DR. Cardiovascular effects of rilmenidine, moxonidine and clonidine in conscious wild-type and D79N alpha2A-adrenoceptor transgenic mice. Br J Pharmacol 1999; 126: 1522-1530
    CrossrefPubMedGoogle Scholar
  • 21 Yang TT, Liu IM, Wu HT, Cheng JT. Mediation of protein kinase C zeta in mu-opioid receptor activation for increase of glucose uptake into cultured myoblast C2C12 cells. Neurosci Lett 2009; 465: 177-180
    CrossrefPubMedGoogle Scholar
  • 22 Alonso-Castro AJ, Zapata-Bustos R, Dominguez F, Garcia-Carranca A, Salazar-Olivo LA. Magnolia dealbata Zucc and its active principles honokiol and magnolol stimulate glucose uptake in murine and human adipocytes using the insulin-signaling pathway. Phytomedicine 2011; 18: 926-933
    CrossrefPubMedGoogle Scholar
  • 23 Alonso-Castro AJ, Salazar-Olivo LA. The anti-diabetic properties of Guazuma ulmifolia Lam are mediated by the stimulation of glucose uptake in normal and diabetic adipocytes without inducing adipogenesis. J Ethnopharmacol 2008; 118: 252-256
    CrossrefPubMedGoogle Scholar
  • 24 Yang TT, Ku PM, Hsu CT, Chung HH, Lee WJ, Cheng JT. Mediation of AMP Kinase in the Increase of Glucose Uptake in L6 Cells Induced by Activation of Imidazoline I-2 Receptors. Horm Metab Res 2012; Dec 7 [Epub ahead or print]
    PubMedGoogle Scholar
  • 25 Bhaskar JJ, Salimath PV, Nandini CD. Stimulation of glucose uptake by Musa sp. (cv. elakki bale) flower and pseudostem extracts in Ehrlich ascites tumor cells. J Sci Food Agric 2011; 91: 1482-1487
    CrossrefPubMedGoogle Scholar
  • 26 Piletz JE, Wang G, Zhu H. Cell signaling by imidazoline-1 receptor candidate, IRAS, and the nischarin homologue. Ann N Y Acad Sci 2003; 1009: 392-399
    CrossrefPubMedGoogle Scholar
  • 27 Zhang J, Abdel-Rahman AA. Inhibition of nischarin expression attenuates rilmenidine-evoked hypotension and phosphorylated extracellular signal-regulated kinase 1/2 production in the rostral ventrolateral medulla of rats. J Pharmacol Exp Ther 2008; 324: 72-78
    PubMedGoogle Scholar
  • 28 Sano H, Liu SC, Lane WS, Piletz JE, Lienhard GE. Insulin receptor substrate 4 associates with the protein IRAS. J Biol Chem 2002; 277: 19439-19447
    CrossrefPubMedGoogle Scholar
  • 29 Sun Z, Chang CH, Ernsberger P. Identification of IRAS/Nischarin as an I1-imidazoline receptor in PC12 rat pheochromocytoma cells. J Neurochem 2007; 101: 99-108
    CrossrefPubMedGoogle Scholar
  • 30 Li F, Wu N, Su R, Chen Y, Lu X, Liu Y, Li J. Imidazoline receptor antisera-selected/Nischarin regulates the effect of agmatine on the development of morphine dependence. Addiction Biol 2012; 17: 392-408
    CrossrefPubMedGoogle Scholar
  • 31 Zhang J, Abdel-Rahman AA. Inhibition of nischarin expression attenuates rilmenidine-evoked hypotension and phosphorylated extracellular signal-regulated kinase 1/2 production in the rostral ventrolateral medulla of rats. J Pharmacol Exp Therap 2008; 324: 72-78
    PubMedGoogle Scholar
  • 32 Baranwal S, Wang Y, Rathinam R, Lee J, Jin L, McGoey R, Pylayeva Y, Giancotti F, Blobe GC, Alahari SK. Molecular characterization of the tumor-suppressive function of nischarin in breast cancer. J Nat Cancer Inst 2011; 103: 1513-1528
    CrossrefPubMedGoogle Scholar
  • 33 Wang B, Liu Y, Shan Y, Yao Z, Liu X, Su R, Sun Q, Cong Y, Li J. Generation and characterization of novel human IRAS monoclonal antibodies. J Biomed Biotechnol 2009; 2009: 973754
    PubMedGoogle Scholar
  • 34 Gongadze NV, Antelava NA, Kezeli TD. Imidazoline receptors. Georgian Med News 2008; 44-47
    PubMedGoogle Scholar
  • 35 Nechifor M, Ciubotariu D. Behavioral involvement of imidazoline system. Revista Med-Chirurg Soc Med Nat Iasi 2012; 116: 552-556
    PubMedGoogle Scholar
  • 36 Kawamura K, Yui J, Konno F, Yamasaki T, Hatori A, Wakizaka H, Fujinaga M, Kumata K, Yoshida Y, Ogawa M, Nengaki N, Yanamoto K, Fukumura T, Zhang MR. Synthesis and evaluation of PET probes for the imaging of I2 imidazoline receptors in peripheral tissues. Nucl Med Biol 2012; 39: 89-99
    CrossrefPubMedGoogle Scholar
  • 37 Morgan NG, Chan SL. Imidazoline binding sites in the endocrine pancreas: can they fulfil their potential as targets for the development of new insulin secretagogues?. Curr Pharmaceut Design 2001; 7: 1413-1431
    CrossrefPubMedGoogle Scholar
  • 38 Malloy BJ, Price DT, Price RR, Bienstock AM, Dole MK, Funk BL, Rudner XL, Richardson CD, Donatucci CF, Schwinn DA. Alpha1-adrenergic receptor subtypes in human detrusor. J Urol 1998; 160: 937-943
    CrossrefPubMedGoogle Scholar
  • 39 Hosoda C, Koshimizu TA, Tanoue A, Nasa Y, Oikawa R, Tomabechi T, Fukuda S, Shinoura H, Oshikawa S, Takeo S, Kitamura T, Cotecchia S, Tsujimoto G. Two alpha1-adrenergic receptor subtypes regulating the vasopressor response have differential roles in blood pressure regulation. Mol Pharmacol 2005; 67: 912-922
    PubMedGoogle Scholar
  • 40 Devic E, Xiang Y, Gould D, Kobilka B. Beta-adrenergic receptor subtype-specific signaling in cardiac myocytes from beta(1) and beta(2) adrenoceptor knockout mice. Mol Pharmacol 2001; 60: 577-583
    PubMedGoogle Scholar
  • 41 Spitzer N, Edwards DH, Baro DJ. Conservation of structure, signaling and pharmacology between two serotonin receptor subtypes from decapod crustaceans, Panulirus interruptus and Procambarus clarkii. J Exp Biol 2008; 211: 92-105
    CrossrefPubMedGoogle Scholar